Sanofi - Company Profile

Powered by

All the data and insights you need on Sanofi in one report.

  • Save hours of research time and resources with
    our up-to-date Sanofi Strategy Report

  • Understand Sanofi position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Business Description

Sanofi is a pharmaceutical company engaged in the development, manufacturing, and distribution of a broad range of prescription medicines, consumer healthcare products and generic products worldwide. The company operates through two operating segments: Biopharma and Consumer Healthcare.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

R&D Overview

Sanofi’s research and development activities focus on therapy areas such as immunology and inflammation, multiple sclerosis, oncology, neurology, rare diseases and rare blood disorders. The company’s R&D focused on the transformative therapies are fitusiran and efanesoctocog alfa (hemophilia); amlitelimab (Immunology & Inflammation); tolebrutinib (multiple sclerosis); and nirsevimab (prevention of respiratory syncytial virus). Sanofi is dedicated to creating new medicines that are inspired by patient insights and grounded in exceptional scientific research. Its focus lies in providing support to the millions of individuals who are affected by neurological disorders. By harnessing revolutionary technologies, Sanofi scientists are actively working on the development of targeted therapies that have the potential to modify the course of diseases like multiple sclerosis (MS), inflammatory diseases and amyotrophic lateral sclerosis (ALS). The company has a remarkable history of innovation in the field of hematology, starting from the pioneering development of extended half-life clotting factors for the treatment of hemophilia A and B. Furthermore, they have achieved significant milestones by introducing the first approved treatments for acquired thrombotic thrombocytopenic purpura (aTTP) and cold agglutinin disease. This legacy of innovation underscores their commitment to advancing medical solutions in the field of hematology. The company invests on major projects, including six therapies in immunology, hematology, neurology, vaccines and oncology. Sanofi is deeply committed to making important advancements in the field of rare diseases, with a focus on discovering, developing, and delivering new options for individuals affected by such conditions. The dedicated teams at Sanofi are actively working on the development of innovative medicines for disorders like Fabry, Gaucher, and Pompe diseases. Additionally, they are making significant progress towards finding new treatments for patients with acid sphingomyelinase deficiency (ASMD) to address unmet medical needs in these areas. Its research and development teams are also actively engaged in the development of vaccine antigens, which are essential molecules that stimulate the immune response in the body to fight against disease-causing pathogens. In addition to their focus on infectious diseases, Sanofi also explores the potential of vaccines in preventing chronic diseases. The company conducts R&D activities for pharmaceuticals at four operational sites located in France: Chilly-Mazarin/Longjumeau, Montpellier, Strasbourg and Vitry-sur-Seine/Alfortville; three sites in the rest of Europe (Germany, Belgium, and the Netherlands); six sites in the United States: Bridgewater, Cambridge, Framingham/Waltham, Great Valley, San Francisco, and San Diego; and three sites located in Asia in China (Beijing, Shanghai and Chengdu). The vaccines research and development sites are in Swiftwater, Cambridge and Orlando (the US); Marcy-l’Etoile/Lyon (France); and Toronto (Canada). In FY2023, the company spent EUR6,728 million on R&D, which as a percentage of revenue, and grew 0.3% YoY.

Business Segments

Overview

It offers commercial operations, research, development and production activities. It also includes General Medicines, Specialty Care, and Vaccines franchises for all geographical territories.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Overview

Develops and sells consumer healthcare products. Key products and brands include Allegra, Doliprane, Enterogermina, Pharmaton and Gold Bond among others.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Subscribe for access to business segment analysis Subscribe for access to business segment analysis Find out more



Geographical Segments

Target Markets

Includes operations of Western Europe, Eastern Europe, Israel and Ukraine.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Target Markets

Comprises operations of Brazil, China, Japan, and Russia.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Gain a 360-degree view of Sanofi and make more informed decisions for your business Gain a 360-degree view of Sanofi and make more informed decisions for your business Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer